Quantification of change in pigment epithelial detachment volume and morphology after transition to intravitreal aflibercept in eyes with recalcitrant neovascular AMD: 18-Month results

Ophthalmic Surgery Lasers and Imaging Retina

Volumn 46, Issue 6, 2015, Pages 638-641

  Kanesa Thasan, Aditya ^a   Grewal, Dilraj S ^a,b   Gill, Manjot K ^a   Lyon, Alice T ^a   Mirza, Rukhsana G ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b DUKE UNIVERSITY EYE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; RANIBIZUMAB; ANGIOGENESIS INHIBITOR; HYBRID PROTEIN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR; VEGFA PROTEIN, HUMAN;

AGE RELATED MACULAR DEGENERATION; AGED; ARTICLE; CLINICAL ARTICLE; FEMALE; FOLLOW UP; HUMAN; MALE; PRIORITY JOURNAL; RETINA DETACHMENT; RETROSPECTIVE STUDY; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; VERY ELDERLY; VISUAL ACUITY; WET MACULAR DEGENERATION; ANTAGONISTS AND INHIBITORS; DRUG RESISTANCE; DRUG SUBSTITUTION; INTRAVITREAL DRUG ADMINISTRATION; MACULAR DEGENERATION; OPTICAL COHERENCE TOMOGRAPHY; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PIGMENT EPITHELIUM; RETINAL DETACHMENT; RETINAL NEOVASCULARIZATION;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; BEVACIZUMAB; DRUG RESISTANCE; DRUG SUBSTITUTION; FEMALE; HUMANS; INTRAVITREAL INJECTIONS; MACULAR DEGENERATION; MALE; RANIBIZUMAB; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; RETINAL DETACHMENT; RETINAL NEOVASCULARIZATION; RETINAL PIGMENT EPITHELIUM; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 84937041537     PISSN: 23258160     EISSN: 23258179     Source Type: Journal    
DOI: 10.3928/23258160-20150610-07     Document Type: Article

References (15)

1. Bakall B, Folk JC, Boldt HC et al. Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab. Am J Ophthalmol. 2013; 156(1):15-22.e1.
2. Cho H, Shah CP, Weber M, Heier JS. Aflibercept for exudative AMD with persistent fluid on ranibizumab and/or bevacizumab. Br J Ophthalmol. 2013;97(8):1032-1035.
3. Kumar N, Marsiglia M, Mrejen S et al. Visual and anatomical outcomes of intravitreal aflibercept in eyes with persistent subfoveal fluid despite previous treatments with ranibizumab in patients with neovascular age-related macular degeneration. Retina. 2013;33(8):1605-1612.
4. Grewal DS, Gill MK, Sarezky D, Lyon AT, Mirza RG. Visual and anatomical outcomes following intravitreal aflibercept in eyes with recalcitrant neovascular age-related macular degeneration: 12-month results. Eye (Lond). 2014;28(7): 895-899.
5. Ho VY, Yeh S, Olsen TW et al. Short-term outcomes of aflibercept for neovascular age-related macular degeneration in eyes previously treated with other vascular endothelial growth factor inhibitors. Am J Ophthalmol. 2013; 156(1):23-28.e2.
6. Chang AA, Li H, Broadhead GK et al. Intravitreal aflibercept for treatment-resistant neovascular age-related macular degeneration. Ophthalmology. 2014;121(1):188-192.
7. Zayit-Soudry S, Moroz I, Loewenstein A. Retinal pigment epithelial detachment. Surv Ophthalmol. 2007;52(3):227-243.
8. Penha FM, Gregori G, Garcia Filho CA et al. Quantitative changes in retinal pigment epithelial detachments as a predictor for retreatment with anti-VEGF therapy. Retina. 2013;33(3):459-466.
9. Schneider CA, Rasband WS, Eliceiri KW. NIH Image to Image J: 25 years of image analysis. Nat Meth. 2012;9(7): 671-675.
10. Grossniklaus HE, Ling JX, Wallace TM et al. Macrophage and retinal pigment epithelium expression of angiogenic cytokines in choroidal neovascularization. Mol Vis. 2002;8: 119-126.
11. Schlingemann RO. Role of growth factors and the wound healing response in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2004;242(1):91-101.
12. Ferrone PJ, Anwar F, Naysan J et al. Early initial clinical experience with intravitreal aflibercept for wet age-related macular degeneration. Br J Ophthalmol. 2014;98(Suppl 1):i17-21.
13. Patel KH, Chow CC, Rathod R et al. Rapid response of retinal pigment epithelial detachments to intravitreal aflibercept in neovascular age-related macular degeneration refractory to bevacizumab and ranibizumab. Eye (Lond). 2013;27(5):663-667.
14. Yamashita M, Nishi T, Hasegawa T, Ogata N. Response of serous retinal pigment epithelial detachments to intravitreal aflibercept in polypoidal choroidal vasculopathy refractory to ranibizumab. Clin Ophthalmol. 2014;8:343-346.
15. Rahimy E, Freund KB, Larsen M et al. Multilayered pigment epithelial detachment in neovascular age-related macular degeneration. Retina. 2014;34(7):1289-1295.